360
Participants
Start Date
July 31, 2010
Primary Completion Date
July 31, 2018
Study Completion Date
July 31, 2018
SIR-Spheres
One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
Sorafenib tosylate
Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
National Taiwan University Hospital, Taipei City
Taipei Veterans General Hospital, Taipei City
China Medical University Hospital, Taichung
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City
Auckland City Hospital, Grafton
St. Luke's Medical Center, Philippines, Quezon City
Makati Medical Center, Manila
The Brunei Cancer Centre, Kampong Jerudong
Chulabhorn Hospital, Bangkok
Penang Adventist Hospital, George Town
Yangon GI & Liver Centre, Yangon
Cipto Mangunkusumo Hospital ,University of Indonesia, Jakarta
University of Udayana, Rumah Sakit Sanglah, Indonesia, Denpasar
National University Hospital, Singapore
Singapore General Hospital, Singapore
National Cancer Center Singapore, Singapore
National Cancer Center of Mongolia, Ulaanbaatar
Khoo Teck Puat Hospital, Singapore
Queen Mary Hospital, Hong Kong
Sarawak General Hospital, Kuching
University Malaya Medical Center, Kuala Lumpur
The Medical City, Pasig
Davao Doctors Hospital, Davao City
Chang Gung Memorial Hospital, Taoyuan District
Severance Hospital, Yonsei University College of Medicine, Seoul
Korea University Anam Hospital, Seoul
Seoul St. Mary's Hospital, Seoul
Asan Medical Center, Seoul
Seoul National University Bundang Hospital, Seoul
Collaborators (1)
National Cancer Centre, Singapore
OTHER
National Medical Research Council (NMRC), Singapore
OTHER_GOV
Singapore Clinical Research Institute
OTHER
Sirtex Medical
INDUSTRY
Singapore General Hospital
OTHER